ABCA1 and ABCG1 expressions are regulated by statins and ezetimibe in Caco-2 cells

Drug Metabolism and Drug Interactions

Volumn 26, Issue 1, 2011, Pages 33-36

  Genvigir, Fabiana D V ^a   Rodrigues, Alice C ^a   Cerda, Alvaro ^a   Hirata, Mario H ^a   Curi, Rui ^a   Hirata, Rosario D C ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

ABCA1; ABCG1; Caco 2 cells; lipid lowering drugs; mRNA expression

Indexed keywords

ABC TRANSPORTER A1; ABC TRANSPORTER G1; ATORVASTATIN; EZETIMIBE; HIGH DENSITY LIPOPROTEIN; MESSENGER RNA; SIMVASTATIN;

ARTICLE; CONCENTRATION RESPONSE; DOWN REGULATION; GENE EXPRESSION; HUMAN; HUMAN CELL; INTESTINE CELL; LIPOPROTEIN METABOLISM; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION;

ANTICHOLESTEREMIC AGENTS; ATP-BINDING CASSETTE TRANSPORTERS; AZETIDINES; CACO-2 CELLS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; DRUG THERAPY, COMBINATION; GENE EXPRESSION REGULATION; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; POLYMERASE CHAIN REACTION; PYRROLES; RNA, MESSENGER; SIMVASTATIN; TIME FACTORS;

EID: 79956340133     PISSN: 07925077     EISSN: 07925077     Source Type: Journal    
DOI: 10.1515/DMDI.2011.101     Document Type: Article

References (18)

1. Bays HE, Neff D, Tomassini JE, Tershakovec AM. Ezetimibe: cholesterol lowering and beyond. Expert Rev Cardiovasc Ther 2008;6:447-70.
2. Toth PP. Drug treatment of hyperlipidaemia: a guide to the rational use of lipid-lowering drugs. Drugs 2010;70:1363-79.
3. Pearson TA, Denke MA, McBride PE, Battisti WP, Brady WE, Palmisano J. A community-based, randomized trial of ezetimibe added to statin therapy to attain NCEP ATP III goals for LDL cholesterol in hypercholesterolemic patients: the ezetimibe add-on to statin for effectiveness (EASE) trial. Mayo Clin Proc 2005;80:587-95. (Pubitemid 40628813)
4. Sviridov D, Nestel P, Watts G. Statins and metabolism of high density lipoprotein. Cardiovasc Hematol Agents Med Chem 2007;5:215-21. (Pubitemid 47180852)
5. Genvigir FD, Rodrigues AC, Cerda A, Arazi SS, Willrich MA, Oliveira R, et al. Effects of lipid-lowering drugs on reverse cholesterol transport gene expressions in peripheral blood mononu-clear and HepG2 cells. Pharmacogenomics 2010;11:1235-46.
6. Rodrigues AC, Curi R, Genvigir FD, Hirata MH, Hirata RD. The expression of efflux and uptake transporters are regulated by statins in Caco-2 and HepG2 cells. Acta Pharmacol Sin 2009;30:956-64.
7. Davignon J, Dubuc G. Statins and ezetimibe modulate plasma proprotein convertase subtilisin kexin-9 (PCSK9) levels. Trans Am Clin Climatol Assoc 2009;120:163-73.
8. Field FJ, Born E, Mathur SN. Stanol esters decrease plasma cholesterol independently of intestinal ABC sterol transporters and Niemann-Pick C1-like 1 protein gene expression. J Lipid Res 2004;45:2252-9. (Pubitemid 39602972)
9. Tamehiro N, Shigemoto-Mogami Y, Kakeya T, Okuhira K, Suzuki K, Sato R, et al. Sterol regulatory element-binding pro-tein-2-and liver X receptor-driven dual promoter regulation of hepatic ABC transporter A1 gene expression: mechanism underlying the unique response to cellular cholesterol status. J Biol Chem 2007;282:21090-9. (Pubitemid 47099939)
10. Field FJ, Watt K, Mathur SN. Origins of intestinal ABCA1-mediated HDL-cholesterol. J Lipid Res 2008;49:2605-19.
11. SanéAT, Sinnett D, Delvin E, Bendayan M, Marcil V, Ménard D, et al. Localization and role of NPC1L1 in cholesterol absorption in human intestine. J Lipid Res 2006;47:2112-20. (Pubitemid 44936122)
12. During A, Dawson HD, Harrison EH. Carotenoid transport is decreased and expression of the lipid transporters SR-BI, NPC1L1, and ABCA1 is downregulated in Caco-2 cells treated with ezetimibe. J Nutr 2005;135:2305-12. (Pubitemid 41429582)
13. Repa JJ, Dietschy JM, Turley SD. Inhibition of cholesterol absorption by SCH 58053 in the mouse is not mediated via changes in the expression of mRNA for ABCA1, ABCG5, or ABCG8 in the enterocyte. J Lipid Res 2002;43:1864-74. (Pubitemid 35315804)
14. Mohammadi A, Macri J, Newton R, Romain T, Dulay D, Adeli K. Effects of atorvastatin on the intracellular stability and secretion of apolipoprotein B in HepG2 cells. Arterioscler Thromb Vasc Biol 1998;18:783-93. (Pubitemid 28267659)
15. Bonn V, Cheung RC, Chen B, Taghibiglou C, Van Iderstine SC, Adeli K. Simvastatin, an HMG-CoA reductase inhibitor, induces the synthesis and secretion of apolipoprotein AI in HepG2 cells and primary hamster hepatocytes. Atherosclerosis 2002;163:59-68. (Pubitemid 34615726)
16. Brunham LR, Kruit JK, Iqbal J, Fievet C, Timmins JM, Pape TD, et al. Intestinal ABCA1 directly contributes to HDL biogenesis in vivo. J Clin Invest 2006;116:1052-62.
17. Tarr PT, Tarling EJ, Bojanic DD, Edwards PA, Baldán A. Emerging new paradigms for ABCG transporters. Biochim Biophys Acta 2009;1791:584-93.
18. Kennedy MA, Barrera GC, Nakamura K, Baldán A, Tarr P, Fishbein MC, et al. ABCG1 has a critical role in mediating cholesterol efflux to HDL and preventing cellular lipid accumulation. Cell Metab 2005;1:121-31. (Pubitemid 43977167)